| Umsatz in Mio. | - |
| Operatives Ergebnis (EBIT) in Mio. | - |
| Jahresüberschuss in Mio. | - |
| Umsatz je Aktie | - |
| Gewinn je Aktie | - |
| Gewinnrendite | - |
| Umsatzrendite | - |
| Return on Investment | - |
| Marktkapitalisierung in Mio. | 17.420 $ |
| KGV (Kurs/Gewinn) | - |
| KBV (Kurs/Buchwert) | - |
| KUV (Kurs/Umsatz) | - |
| Eigenkapitalrendite | - |
| Eigenkapitalquote | - |
| Aktienanzahl | 45,56 Mio. |
| Streubesitz | 0,89% |
| Aktientyp | Stammaktie |
| +11,69% | Vanguard Group Inc |
| +10,11% | BlackRock Inc |
| +8,04% | Baillie Gifford & Co Limited. |
| +4,59% | State Street Corporation |
| +3,34% | PRIMECAP Management Company |
| +3,22% | Wellington Management Company LLP |
| +2,96% | Generation Investment Management LLP |
| +2,81% | Renaissance Technologies Corp |
| +2,80% | Brown Capital Management, LLC |
| +2,78% | Winslow Capital Management, LLC |
| +2,67% | AllianceBernstein L.P. |
| +2,27% | Geode Capital Management, LLC |
| +2,17% | William Blair Investment Management, LLC |
| +1,62% | Ownership Capital BV |
| +1,40% | Bank of New York Mellon Corp |
| +1,12% | Macquarie Group Ltd |
| +1,10% | Amvescap Plc. |
| +1,09% | Palo Alto Investors, LLC |
| +1,07% | Northern Trust Corp |
| +0,95% | Jackson Square Partners, LLC |
| +31,31% | Weitere |
| +0,89% | Streubesitz |
J&J wollen Abiomed übernehmen
https://www.nasdaq.com/articles/jj-to-buy-abiomed-in-%2416.6-bln-deal
FDA Zulassung für Impella RP Flex (Rechtsherzinsuffizienz)
https://www.fiercebiotech.com/medtech/abiomed-scores-fda-clearance-easier-wear-pump-right-side-heart-failure